Quantcast
 
New ETF Book by Larry Connors - Click here to read more


 

MultiVu Video Feed: SCIELE PHARMA ANNOUNCES AVAILABILITY OF ULESFIA(TM), FIRST AND ONLY FDA-APPROVED NON-NEUROTOXIC HEAD LICE TREATMENT

Wed. August 05, 2009; Posted: 11:00 AM
Stocks RSS
Aug 05, 2009 /PRNewswire via COMTEX/ -- SCRX | Quote | Chart | News | PowerRating -- Sciele Pharma, Inc., a Shionogi Company, today announced the availability of Ulesfia (Benzyl Alcohol Lotion 5%), the first and only prescription medication that kills head lice by asphyxiation without potential neurotoxic side effects. Approved by the U.S. Food & Drug Administration (FDA), Ulesfia is available now by prescription nationwide in time for peak head lice season as children will shortly be headed back to school.

Each year, approximately 6 to 12 million children between the ages of 3 and 12 years are infested with head lice, parasites that survive by injecting small amounts of saliva and removing small amounts of blood from the scalp every few hours. To survive, lice breathe through sophisticated breathing holes that close upon contact with most liquids, allowing the lice to go into suspended animation and survive for hours without respiration. Ulesfia's unique mechanism of action is facilitated through the use of benzyl alcohol which prevents lice from closing their breathing holes, thereby asphyxiating them and causing death. Ulesfia is an effective head lice treatment that does not contain harsh chemicals and addresses the increasing resistance of lice to therapies that contain neurotoxic chemicals.

Full prescribing information for Ulesfia (Benzyl Alcohol Lotion 5%) is available at www.sciele.com.

    SATELLITE FEEDS:
    Wednesday, August 5th, 2009        Thursday, August 6th, 2009
    1:00 PM - 1:15 PM ET               1:00 PM - 1:15 PM ET
    AMC 3                              AMC 3
    C-Band                             C-Band
    Transponder 3                      Transponder 3
    Downlink Freq. 3760 Horizontal     Downlink Freq. 3760 Horizontal

NEWS: Unique Product Asphyxiates Head Lice, Can Help With Outbreaks as Children Head Back to School

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/37282/consumer.html


    SOUNDBITES:
    * Ronald Hansen, M.D., Chief of Pediatric Dermatology, Phoenix Children's
      Hospital
    * Judith O'Haver, RN, MS, CPNP, Nurse Practitioner, Phoenix Children's
      Hospital

    B-ROLL INCLUDES:
    * Children at camp and school - Head lice images - Young girl patient
      with doctor -- Nurse combing out girl's hair - Ulesfia product shot

VIDEO PROVIDED BY: Sciele Pharma, Inc., a Shionogi Company

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3

SOURCE Sciele Pharma, Inc., a Shionogi Company

http://www.sciele.com
For full details for SCRX click here.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [SCRX]
  UPCOMING EVENTS
Learn new strategies, how to trade in this market, and the stocks you should be focusing on each day. Join us for our free 20 minute tele-seminars during the week.
* Attendance is strictly limited and are filled on a first-come, first-served basis.
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302

© Copyright 2009 The Connors Group, Inc.


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2009 The Connors Group, Inc.